Zusammenfassung
Die arterielle Hypertonie ist die häufigste Herz-Kreislauf-Erkrankung überhaupt, und sie ist eine Alterskrankheit. In den westlichen Industrienationen sind die älteren Menschen (>65 Jahre) die am stärksten wachsende Bevölkerungsgruppe.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Alderman MH (1999) A new model of risk: implications of increasing pulse pressure and systolic blood pressure on cardiovascular disease. J Hypertens Suppl 17(5):S25–S28
Deutsche Hochdruckliga (DHL) (2006) AWMF-Leitlinie arterielle Hypertonie 2003–2008. http://www.uni-duesseldorf.de/AWMF/ll/046-001.htm. Gesehen 5.7.2008
Beckett NS, Peters R, Fletcher AE et al. (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898
Boersma E, Keil U, De Bacquer D et al. (2003) Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 21:1831–1840
Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ (2001) Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 23:1999–2010
Düsing R (2001) Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 3:488–492
Hasford J, Schröder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G (2000) Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 63:1055–1061
Hense HW (2000) MONICA Study: Epidemiology of arterial hypertension and implications for its prevention. 10-year results of the MONICA Study Augsburg). Dtsch Med Wochenschr 125:1397–1402
Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC (1994) Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 121(5):355–362
Lawes C, Vander Hoorn S, Rodgers A (2008) for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371:1513–1518
Löwel H, Kuch B, Meisinger C, Müller J, Hörmann A (2001) Koronarpatient im Alter — epidemiologische Sicht. Herzmedizin 18:110–119
Mancia G, De Backer G, Dominiczak A et al. (2007) Guidelines for the management of arterial Hypertension. Eur Heart J 28:1462–1536
Milchak JL, Carter BL, Ardery G, Dawson JD, Harmston M, Franciscus CL (2008) Physician adherence to blood pressure guidelines and its effect on seniors. Pharmacotherapy 28(7):843–851
Plouin PF, Rossignol P, Bobrie G (2006) Hypertension in the elderly. Bull Acad Natl Med 190:793–805
Sagie A, Larson MG, Levy D (1993) The natural history of borderline isolated systolic hypertension. N Engl J Med 329(26):1912–1917
Staessen JA, Thijs L, Fagard R et al. (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282:539–546
Sytkowski PA, D’Agostino RB, Belanger AJ, Kannel WB (1996) Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 93:697–703
Wittchen HU, Glaesmer H, März W (2005) Cardiovascular risk factors in primary care: methods and baseline prevalence rates — the DETECT program. Curr Med Res Opin 21:619–630
Literatur
Ahmed A, Husain A, Love TE, et al. (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439
Arzneimittelkommission der deutschen ärzteschaft (2007) Chronische Herzinsuffizienz. Arzneiverordnung in der Praxis, Bd 34, Sonderheft 3 (Therapieempfehlungen), April 2007, http://www.akdae.de/en/35/65-Herzinsuffizienz-2007-3Auflage.pdf. Gesehen 6.4.09
Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M; TIME-CHF-Investigators (2006) Management of elderly patients with congestive heart failure — design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151(5):949–955
Bulpitt CJ (2005) Secondary prevention of coronary heart disease in the elderly. Heart 91:396–400
Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC (1999) Incidence and aetiology of heart failure; a population-based study. Eur Heart J 20(6):421–428
Deedwania PC, Gottlieb S, Ghali JK, et al. (2004) Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol XL in elderly patients with heart failure. Eur Heart J 25:1300–1309
Flather MD, Yusuf S, Kober L, et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581
Flather MD, Shibata MC, Coats AJ et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215–225
Ho KKL, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure — the Framingham Study. J Am Coll Cardiol 22:A6–A13
Hunt SA, Abraham WT, Chin MH, et al. (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154–e235
Kannel WB, Belanger AJ (1991) Epidemiology of heart failure. Am Heart J 121:951–957
Leibundgut G von, Pfisterer M, Brunner-La Rocca HP (2007) Drug treatment of chronic heart failure in the elderly. Drugs Aging 24(12):991–1006
Zuccalà G, Onder G, Marzetti E et al. (2005) Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 26(3):226–233
Literatur
Adams HP Jr, del Zoppo G, Alberts MJ et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38(5):1655–1711
Adams RJ, Albers G, Alberts MJ et al. (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39(5):1647–1652
Amarenco P, Bogousslavsky J, Callahan A 3rd et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559
Aronow WS, Ahn C (1996) Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 77:864–866
Bach RG, Cannon CP, Weintraub WS et al. (2005) The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 141(3):186–195
Baigent C, Keech A, Kearney PM et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278
Boersma E, Harrington RA, Moliterno DJ et al. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302):189–198
COMMIT Collaborative Group (2005) Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 366:1622–1632
Döser S, März W, Reinecke MF et al. (2004) Empfehlungen zur Statintherapie im Alter: Daten und Consensus. Internist (Berl) 45(9):1053–1062
Gesundheitsberichterstattung des Bundes (2009) Daten zu Herzinfarkten in der Region Augsburg. Mortalität, Morbidität, Letalität, Vorerkrankungen, medizinische Versorgung. http://www.gbe-bund.de/gbe10/ergebnisse.prc_tab?fid=6770&suchstring=&query_id=&sprache=D&fund_typ=TAB&methode=&vt=&verwandte=1¶ge_ret=0&seite=1&p_lfd_nr=20&p_news=&p_sprachkz=D&p_uid=gasts&p_aid=93524339&hlp_nr=2&p_janein=J. Gesehen 22.11.2009
Grundy SM, Cleeman JI, Merz CNB et al. (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227–239
Krumholz HM, Radford MJ, Ellerbeck EF et al. (1995) Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 92(10):2841–2847
Kyriakides ZS, Kourouklis S, Kontaras K (2007) Acute coronary syndromes in the elderly. Drugs Aging 24(11):901–912
Lenderink T, Boersma E, Gitt AK et al. (2006) Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than nonusers: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 27(15):1799–1804
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343(8893):311–322
Petersen S, Peto V, Scarborough P, Rayner M (2005) Coronary heart disease statistics. London, British Heart Foundation
Schuler J, Maier B, Behrens S, Thimme W (2006) Present treatment of acute myocardial infarction in patients over 75 years—data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol 95(7):360–367
Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630
Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW et al. (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28(13):1598–1660
The TIME Investigators (2001) Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 358:951–957
Literatur
Alikhan R, Cohen AT, Combe S et al. (2003) Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 14(4):341–346
Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7):e257–e354
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453S
Nieuwlaat R, Capucci A, Lip GY et al. (2006) Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27(24):3018–3026
Rossol-Haseroth K, Vogel CU, Reinecke F et al. (2002) Empfehlungen zur Thromboembolieprophylaxe bei internistischen Patienten im Alter. Internist (Berl) 43(9):1134–1147
Roy D, Talajic M, Nattel S et al. (2008) Atrial fibrillation and congestive heart failure investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358(25):2667–2677
Savelieva I, Camm AJ (2001) Clinical trends in atrial fibrillation at the turn of the millenium. J Intern Med 250(5):369–372
Spyropoulos AC, Merli G (2006) Management of venous thromboembolism in the elderly. Drugs Aging 23(8):651–671
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (2008) Fluoroquinolones: psychiatric adverse effects. Prescrire Int 17(93):20
Board M, Allen SC (2006) A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract 60(5):510–513
Buhl R, Berdel D, Criée CP et al. (2006) Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 60(3):139–177
GOLD (Global Initiative for Chronic Obstructive Lung Disease) (2007) Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org.Gesehen11.8.08
Jara M, Lanes SF, Wentworth C 3rd, May C, Kesten S (2007) Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 30(12):1151–1160
Müller D, Szucs TD (2007) Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 35(5):308–319
Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442
Rabe KF, Hurd S, Anzueto A et al. (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176(6):532–555
Salpeter SR (2007) Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis 2(1):11–18
Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, Buist AS (2007) COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 131(1):29–36
Weel C van (1996) Chronic diseases in general practice: the longitudinal dimension. Eur J Gen Pract 2:17–21
Literatur
Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026–2032
Dachverband Osteologie (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen, Langfassung: http://www.dv-osteologie.org/uploads/leitlinien/DVO-Leitlinie%202009%20Langfassung%2015.10.2009.pdf, Kurzfassung: http://www.dv-osteologie.org/uploads/leitlinien/DVO-Leitlinie%202009%20Kurzfassung%2015.10.09_1.pdf. Gesehen 7.12.2009
Dachverband der Deutschsprachigen Osteologischen Fachgesellschaften (2006) Kitteltaschenfassung 2006 der Leitlinie des Dachverbands der Deutschsprachigen Osteologischen Fachgesellschaften zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr. http://www.dv-osteologie.org/uploads/leitlinien/Kitteltasche_DVO-Leitlinien_15-03-06.pdf. Gesehen 7.12.09
Duque G, Mallet L, Roberts A, Gingrass S, Kremer R, Sainte-Marie LG, Kiel DP (2007) To treat or not to treat, that is the question: proceedings of the Quebec symposium for the treatment of osteoporosis in long-term care institutions,.Saint-Hyacinthe, Quebec, November 5th, 2004. J Am Med Dir Assoc 8(3 Suppl 2):e67–e73
Looker AC, Orwoll ES, Johnston CC Jr et al. (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768
Lyles KW, Colón-Emeric CS, Magaziner JS et al. (2007) HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809
Literatur
Abram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B (2006) Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications 20:402–408
ACCORD (The Action to Control Cardiovascular Risk in Diabetes Study Group) (2008) Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358:2545–2559
ADVANCE (The ADVANCE Collaborative Group) (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
Allen KV, Frier BM, Strachan MWJ (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490:169–175
American Diabetes Association (2009) Standards of medical care in diabetes. Diabetes Care, 32:S13–S61
Braun A, Muller UA, Leppert K, Schiel R (2004) Structured treatment and teaching of patients with type 2 diabetes mellitus and impaired cognitive function — the DICOF trial. Diabet Med 21:999–1006
Burkhardt H, Karaminejad E, Gladisch R (2006) A short performance-test can help to predict adherence to self-administration of insulin in elderly patients with diabetes. Age Ageing 35:449–452
Cryer PE, Davis SN, Shamon H (2003) Hypoglycemia in Diabetes. Diabetes Care 26:1902–1912
Dargie HJ, Hildebrandt PR, Riegger GA et al. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49(16):1696–1704
DCCT (The Diabetes Control and Complications Trial Research Group) (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
DDG (Deutsche Diabetesgesellschaft) (2009) Diabetes im Alter. http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/Uebersicht_Praxisleitlinien.php. Gesehen 15.12.2009
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705
Duckworth W, Abraira C, Moritz T et al. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139
Erdmann E, Charbonnel B, Wilcox RG et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease. Diabetes Care 30:2773–2778
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
Hader C et al. (2005) Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabet Stoffw 13:31–56
Hauner H (2006) Die Kosten des Diabetes und seiner Komplikationen in Deutschland. Dtsch Med Wochenschr 131:S240–S242
Holstein A, Plaschke A, Egberts EH (2001) Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473
Josephkutty S, Potter JM (1990) Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 7:510–514
Lipscombe LL, Gomes T, Lèvesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2653
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825
Meneilly GS (1999) Pathophysiology of type 2 diabetes in the elderly. Clin Geriatr Med 15:239–253
Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B (2000) Dose response profile of acrabose in older subjects with type 2 diabetes. Am J Med Sci 319:334–337
Moty C, Barberger-Gateau P, De Sarasqueta AM, Teare GF, Henrad JC (2003) Risk adjustment of quality indicators in french long term care facilities for elderly people. A preliminary study. Rev Epidemiol Sante Publique 51:327–338
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S246. http://www.kidney.org/professionals/KDOQI. Gesehen 15.1.2009
Phillips P, Phil D, Rolls B et al. (1984) Reduced thirst after water dehydration in healthy elderly men. N Engl J Med 311:753–759
Pickering G (2004) Frail elderly, nutritional status and drugs. Arch Gerontol Geriatr 38:174–180
Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA (2008) Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. Diab Obes Metab 10:652–660
Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630
Shorr RI, Ray WA, Daugherty JR, Griffin MR (1997) Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 157:1681–1686
Staa T van, Abenhaim L, Monette J (1997) Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50(6):735–741
Skyler JS, Bergenstal R, Bonow RO et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 20;53(3):298–304
The Diabetes Prevention Program Research Group (Prepared by Jill Crandall, David Schade, Yong Ma et al.) (2006) The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol Med Sci 2006, 61A: 1075–1081
Thomson FJ, Masson EA, Leeming JT, Boulton AJ (1991) Lack of knowledge of symproms of hypoglycaemia by elderly diabetic patients. Age Ageing 20:404–406
Thorslund S, Toss G, Nilsson I, Schenk H von, Symbwerg T, Zetterqvist H (1990) Prevalence of protein-energy malnutrition in a large population of elderly people at home. Scand J Prim Health Care 8:243–248
Turnbull PJ, Sinclair AJ (2002) Evaluation of nutritional status and its relationship with functional status in older citizens with diabetes mellitus using the Mini Nutritional Assessment (MNA) tool. A preliminary investigation. J Nutr Health Aging 6:116–120
UKPDS (UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998, 352:854–865
Van Den Berghe G, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367
Staa T van, Abenhaim L, Monette J (1997) Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50(6):735–741
Wehling M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? Ein neues Bewertungssystem: fit for the aged (FORTA). Dtsch Med Wochenschr 133:2289–2291
Yki-Järvinen H, Kauppila M, Kujansuu E et al. (1992) Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426–1433
Zeyfang A, Feucht I, Fetzer G, Bausenhardt C, Ahl V (2001) Eine strukturierte geriatrische Diabetiker-Schulung (SGS) ist sinnvoll. Diabet Stoffw 10:203–207
Literatur
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392
Aarsland D, Ballard C, Walker Z et al. (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618
Adler G, Teufel M, Drach LM (2003) Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 18:653–655
Andersen-Ranberg K, Vasegaard L, Jeune B (2001) Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci 56:152–159
A.T.I. Arzneimittelinformation Berlin (2005) Übersterblichkeit unter Alzheimermittel Galantamin (Reminyl). Arznei-Telegramm 36:24
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209–221
Ballard C, Hanney ML, Theodoulou M et al. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151–157
Benesch G, Frölich L, Riepe MW (2005) Therapie degenerativer Demenzen. In: HC Diener, N Putzki, P Berlit (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. 3. Aufl. Thieme, Stuttgart
Bowler JV (2005) Vascular cognitive impairment. J Neurol Neurosurg Psychiatry 76(Suppl 5):v35–44
Boyle PA, Malloy PF (2004) Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 17:91–99
Buscemi N, Vandermeer B, Hooton N et al. (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385–393
Camicioli R, Fisher N (2004) Progress in clinical neurosciences: Parkinson’s disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 31:7–21
Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett 23(Suppl 1):20–23
Craig D, Birks J (2005) Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev CD004744
Craig D, Birks J (2006) Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev CD004746
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde), DGN (Deutsche Gesellschaft für Neurologie) (2009) S3-Leitlinie Demenzen. www.dgn.org.Gesehen 11.01.2010
Diener HC, Putzki N (Hrsg) (2008) Leitlinien für Diagnostik und Therapie in der Neurologie. Diagnostik degenerativer Demenzen. Thieme, Stuttgart, S 154–167
European Medicines Agency (2009) Committee for medicinal products for human use. Guidelines on medicinal products for the treatment of Alzheimer’s disease and other dementias. http://www.ema.europa.eu/pdfs/human/ewp/0055395en.pdf. Available 11.01.2010
Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518
Ferri CP, Prince M, Brayne C et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117
Fuchs GA, Gemende I, Herting B et al. (2004) Dementia in idiopathic Parkinson’s syndrome. J Neurol 251(Suppl 6):VI/28–32
Hallauer JF, Schons M, Smala A, Berger K (2000) Untersuchungen von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Gesundheitsökon Qualitätsmanag 5:73–79
Hansen RA, Gartlehner G, Webb AP et al. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 3:211–225
Herrmann N, Lanctot KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs 19:91–103
Hogan DB (2006) Donepezil for severe Alzheimer’s disease. Lancet 367:1031–1032
Hogan DB, Patterson C (2002) Progress in clinical neurosciences: Treatment of Alzheimer’s disease and other dementias — review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 29:306–314
Hogan DB, Goldlist B, Naglie G, Patterson C (2004) Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol 3:622–626
Ibach B, Lange K, Haen E (2003) Das cholinerge System und die Therapie der Alzheimer-Demenz. In: Förstl H (Hrsg) Antidementiva. Urban & Fischer, München, S 93–143
IQWIG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) (2009) Memantin bei Alzheimer Demenz. www.iqwig.de/index.404.html. Gesehen 11.01.2010
Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782–792
Lobo A, Launer LJ, Fratiglioni L et al. (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S4–S9
Lopez OL, Becker JT, Wahed AS et al. (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600–607
Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev, CD004747
McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872
Müller U, Wolf H, Kiefer M, Gertz HJ (2003) Ein systematischer Vergleich nationaler und internationaler Demenzrichtlinien. Fortschr Neurol Psychiatr 71:285–295
Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 2005;4:771–780
Ott A, Breteler MM, Harskamp F van, Stijnen T, Hofman A (1998) Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 147:574–580
Samuel W, Caligiuri M, Galasko D et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15:794–802
Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14:191–210
Snitz BE, O’Meara ES, Carlson MC et al.(2009) Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302:2663–2670
Statistisches Bundesamt (2009) Bevölkerung Deutschlands bis 2060 — Ergebnisse der 12. koordinierten Bevölkerungsvorausberechnung, www.destatis.de. Gesehen 11.01.2010
Winblad B, Kilander L, Eriksson S et al. (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 367:1057–1065
Literatur
Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20(10):1255–1263
Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334(2):71–76
Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(Suppl 1):S39–S46
Buhmann C (2008) Diagnostik und Therapie des Morbus Parkinson beim alteren Patienten. NeuroGeriatrie 5:137–145
Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH (2005) Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 28(5):215–219
Csoti I, Fornadi F (2008) Medikamentöse Interaktionen in der Parkinson-Therapie. NeuroGeriatrie 5:160–168
Dell’Agnello G, Ceravolo R, Nuti A et al. (2001) SSSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24(4):221–227
Deutsche Gesellschaft fur Neurologie (2009) Leitlinien der Deutschen Gesellschaft fur Neurologie 2008. Parkinson-Syndrome. Diagnostik und Therapie. http://www.dgn.org.Gesehen 18.12.2009
Ebersbach G (2008) Depressive Störungen bei der Parkinson-Erkrankung. NeuroGeriatrie 5:146–153
Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518
Fahn S, Oakes D, Shoulson I et al. (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508
Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55(6):789–794
Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738
Janno S, Holi M, Tuisku K, Wahlbeck K (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia in patients. Am J Psychiatry 161(1):160–163
Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65(2 Suppl 1): S3–S5
Mitchell SL, Sullivan EA, Lipsitz LA (1997) Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 54(11):1393–1398
Nutt JG (2003) Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson’s disease. Exp Neurol 184(1):9–13
Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23(1):34–44
Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S1–S9
Pollak P, Tison F, Rascol O et al. (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695
Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16(3):278–282
Rascol O, Brooks DJ, Melamed E et al. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463): 947–954
Reddy S, Factor SA, Molho ES, Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17(4):676–681
Rijk MC de, Launer LJ, Berger K (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of populationbased cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–S23
Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36(8):1130–1133
Schwarz J, Storch A (2007) Parkinson-Syndrome. Kohlhammer, Stuttgart
Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson’s disease. J Nerv Ment Dis 178(1):27–31
Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2(8411):1082–1083
Szegedi A, Jansen WT, Willigenburg AP van, van der Meulen E, Stassen HH, Thase ME (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353
The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328(3):176–183
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5):1323–1326
Literatur
Alexopoulos GS (2005) Depression in the elderly. Lancet 365:1961–1970
Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP (2001) The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med Spec No Pharmacotherapy:1–86
Alexopoulos GS, Borson S, Cuthbert BN, Devanand DP, Mulsant BH, Olin JT, Oslin DW (2002) Assessment of late life depression. Biol Psychiatry 52:164–174
Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104
Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E (2000) Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 157:729–736
Cipriani A, Furukawa TA, Salanti G et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758
DGPPN, BAK, KBV et al. (Hrsg) (2009) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression. 1. Aufl, DGPPN, AZQ, AWMF — Berlin, Dusseldorf. http://media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-nvl-unipolaredepression-lf.pdf. Gesehen 11.01.2010
Hawton K, Heeringen K van (2009) Suicide. Lancet 373:1372–1381
Heok KE, Ho R (2008) The many faces of geriatric depression. Curr Opin Psychiatry 21:540–545
Pinquart M, Duberstein PR, Lyness JM (2006) Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 163:1493–1501
Pinquart M, Duberstein PR, Lyness JM (2007) Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: a meta-analysis. Aging Ment Health 11:645–657
Raskin J, Wiltse CG, Siegal A et al. (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909
Tess AV, Smetana GW (2009) Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med 360:1437–1444
Literatur
Ancoli-Israel S, Cooke JR (2005) Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 53:S264–S271
Bloom HG, Ahmed I, Alessi CA et al. (2009) Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 57:761–789
Culberson JW, Ziska M (2008) Prescription drug misuse/abuse in the elderly. Geriatrics 63:22–31
Dolder C, Nelson M, McKinsey J (2007) Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 21:389–405
Dundar Y, Dodd S, Strobl J et al. (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322
Erman MK (2005) Therapeutic options in the treatment of insomnia. J Clin Psychiatry 66(Suppl 9):18–23
Flaherty JH (2008) Insomnia among hospitalized older persons. Clin Geriatr Med 24:51–67
Foley DJ, Monjan A, Simonsick EM et al. (1999) Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 22(Suppl 2):S366–S372
Glass J, Lanctot KL, Herrmann N et al. (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331:1169
Kupfer DJ, Reynolds CF 3rd (1997) Management of insomnia. N Engl J Med 336:341–346
Melton ST, Wood JM, Kirkwood CK (2005) Eszopiclone for insomnia. Ann Pharmacother 39:1659–1666
Svarstad BL, Mount JK (2001) Chronic benzodiazepine use in nursing homes: effects of federal guidelines, resident mix, and nurse staffing. J Am Geriatr Soc 49:1673–1678
Vaz Fragoso CA, Gill TM (2007) Sleep complaints in community-living older persons: a multifactorial geriatric syndrome. J Am Geriatr Soc 55:1853–1866
Wolkove N, Elkholy O, Baltzan M et al. (2007) Sleep and aging: 1. Sleep disorders commonly found in older people. CMAJ 176:1299–1304
Literatur
Ammon HPT (Hrsg) (2001) Arzneimittelneben-und wechselwirkungen. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Andrade SE, Martinez C, Walker AM (1998) Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 51(12):1357–1365
Arzneimittelkommission der deutschen Arzteschaft (2004) Arzneimittelbrief 2003, 37, 6b., Deutsches Arzteblatt 101:A3365
Attal N, Cruccu G, Haanpää M et al. (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169
Baxter H (Ed) (2008) Stockley’s drug interactions 2008. Pharmaceutical Press, London
Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520–1528
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI (1991) Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325(2):87–91
Brattberg G, Parker MG, Thorslund M (1996) The prevalence of pain among the oldest old in Sweden. Pain 67(1):29–34
Brodie MJ, Overstall PW, Giorgi L (1999) Multicentre, doubleblind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 7(1):81–87
Bruckenthal P (2008) Assessment of pain in the elderly adult. Clin Geriatr Med 24(2):213–236
Chan FK, Hung LC, Suen BY et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347(26):2104–2110
Charette SL, Ferrell BA (2007) Rheumatic diseases in the elderly: assessing chronic pain. Rheum Dis Clin North Am 33(1):109–122
Cohen HW, Gibson G, Alderman MH (2000) Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 108(1):2–8
Cruccu G, Anand P, Attal N et al. (2004) EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11(3):153–162
Dworkin RH, Backonja M, Rowbotham MC et al. (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60(11):1524–1534
Ferrell BA, Ferrell BR, Osterweil D (1990) Pain in the nursing home. J Am Geriatr Soc 38(4):409–414
Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118(3):289–305
Frondini C, Lanfranchi G, Minardi M, Cucinotta D (2007) Affective, behavior and cognitive disorders in the elderly with chronic musculoskelatal pain: the impact on an aging population. Arch Gerontol Geriatr 44(Suppl 1):167–171
Gaudreau JD, Gagnon P, Roy MA, Harel F, Tremblay A (2007) Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109(11):2365–2373
Giron MS, Fastbom J, Winblad B (2005) Clinical trials of potential antidepressants: to what extent are the elderly represented: a review. Int J Geriatr Psychiatry 20(3):201–217
Haslam C, Nurmikko T (2008) Pharmacological treatment of neuropathic pain in older persons. Clin Interv Aging (1):111–120
Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 58:265–274
Henry D, Lim LL, Garcia Rodriguez LA et al. (1996) Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312(7046):1563–1566
Hippisley-Cox J, Coupland C, Logan R (2005) Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331(7528):1310–1316
Jüni P, Rutjes AW, Dieppe PA (2202) Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324(7349):1287–1288
Kean WF, Rainsford KD, Kean IR (2008) Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology 6(2):53–75
Lapane KL, Spooner JJ, Mucha L, Straus WL (2001) Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 49(5):577–584
Laurell H, Hansson LE, Gunnarsson U (2006) Acute abdominal pain among elderly patients. Gerontology 52:339–344
Leppik IE, Epilepsy Foundation of America (2005) Choosing an antiepileptic. Selecting drugs for older patients with epilepsy. Geriatrics 60(11):42–47
Mattenklodt P, Ingenhorst A, Wille C et al. (2008) Multimodale Gruppentherapie bei Senioren mit chronischen Schmerzen. Schmerz 22:551–5561
McCleane G (2008) Pain perception in the elderly patient. Clin Geriatr Med 24(2):203–211
McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296(13):1633–1644
McQuay HJ (1997) Opioid use in chronic pain. Acta Anaesthesiol Scand 41(1 Pt 2):175–183
Mercadante S, Arcuri E (2007) Pharmacological management of cancer pain in the elderly. Drugs Aging 24(9):761–776
Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286(8):954–959
Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J (2004) A treatment algorithm for neuropathic pain. Clin Ther. 2004 Jul;26(7):951–979. Review. Erratum in: Clin Ther. 2004 Dec;26(12):2163
Nikolaus T, Zeyfang A (2004) Pharmacological treatment for persisitent non-malignant pain in older persons. Drugs Aging 21:19–41
Pergolizzi J, Boger RH, Budd K et al. (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8(4):287–313
Ruoff GE (2002) Challenges of managing chronic pain in the elderly. Semin Arthritis Rheum 32(3 Suppl 1):43–50
Sauaia A, Min SJ, Leber C, Erbacher K, Abrams F, Fink R (2005) Postoperative pain management in elderly patients: correlation between adherence to treatment guidelines and patient satisfaction. J Am Geriatr Soc 53(2):274–282
Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS (1997) Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272(1):601–608
Schuler MS, Basler HD, Hesselbarth S, Kaluza G, Sohn W, Nikolaus T (2004) Einfluss von Schmerzwahrnehmung, Morbiditat und aktueller Stimmung auf funktionelle Beeintrachtigung Alterer mit chronischen Schmerzen. Z Gerontol Geriatr 37(4):257–264
Semla TP, Beizer JL, Higbee MD (2003) Geriatric dosage handbook. 9th edn, Lexi Comp, Hudson
Tasmuth T, Hartel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6(1):17–24
Vadalouca A, Siafaka I, Argyra E, Vrachnou E, Moka E (2006) Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci 1088:164–186
Van den Bemt PM, Geven LM, Kuitert NA, Risselada A, Brouwers JR (2002) The potential interaction between oral anticoagulants and acetaminophen in everyday practice. Pharm World Sci 24(5):201–204
Waldvogel HH (1996) Analgetika, Antinozizeptiva, Adjuvantien. Handbuch fur die Schmerzpraxis. Springer, Berlin Heidelberg New York Tokyo
Wehling, M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun?. Dtsch Med Wochenschr 133, 2289–2291
WHO (World Health Organisation) (2007) Normative Guidelines on pain management. Geneva WHO. www.who.int/medicines/areas/quality_safety/Tagelphi_study_pain_guidelines.pdf. Gesehen 27.12.2009
WHO (World Health Organisation) (1996) Cancer pain relief with a guide to opioid availability. 2nd edn, WHO, Geneva
Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA (2004) Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc 52(6):867–874
Yost JH, Morgan CJ (1994) Cardiovascular effects of NSAISDs. J Musculoskel Med 11:22–34
Zwakhalen SM, Hamers JP, Abu-Saad HH, Berger MP (2006) Pain in elderly people with severe dementia: a systematic review of behavioural pain assessment tools. BMC Geriatr 6:3
Literatur
Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453
Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36
Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634
André T, Boni C, Mounedji-Boudiaf L et al. (2004) Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351
Ardalan B, Chua L, Tian EM et al. (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9(4):625–630
Ayanian JZ, Zaslavsky AM, Fuchs CS et al. (2003) Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21(7):1293–1300
Begg CB, Carbone PP (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52(11):1986–1992
Boer MF de, Ryckman RM, Pruyn JF, Van den Borne HW (1997) Psychosocial correlates of cancer relapse and survival: A literature review. Patient Edu Counsel (37):215–230
Bergh J, Holmquist M (2001) Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 30:103–108
Bokemeyer C, Aapro MS, Courdi A et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15
Bonneterre J, Thürlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757
Borkowski JM, Duerr M, Donehower RC, Rowinsky EK, Chen TL, Ettinger DS, Grochow LB (1994) Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33(6):493–496
Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25(14):1858–1869
Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A(7):1135–1141
Cameron D, Casey M, Press M et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543
Chapman JA, Meng D, Shepherd L et al. (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100(4):252–260
Christman K, Muss HB, Case LD, Stanley V (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience (see comment). JAMA 268(1):57–62
Coates AS, Keshaviah A, Thürlimann B et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486–492
Cohendy R, Rubenstein LZ, Eledjam JJ (2001) The mini nutritional assessment-short form for preoperative nutritional evaluation of elderly patients. Aging (Milano 13(4):293–297
Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (1999) Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet 354(9173):130–131
Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4(5):419–428
Crivellari D, Bonetti M, Castiglione-Gertsch M et al. (2000) Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 18(7):1412–1422
Crivellari D, Sun Z, Coates AS et al. (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1–98 Trial. J Clin Oncol 26(12):1972–1979
Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM (2006) Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101(10):2308–2318
Cunningham D, Allum WH, Stenning SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20
Cutsem E van, Rivera F, Berry S et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
Edwards BK, Brown ML, Wingo PA et al. (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427
Edwards BK, Howe HL, Ries LA et al. (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94(10):2766–2792
Eichhorst B, Goede V, Hallek M (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50(2):171–178
Eichhorst BF, Busch R, Stilgenbauer S et al. (2009) First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382–3391
Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24(18):2757–2764
Endres HG, Wedding U, Pittrow D, Thiem U, Trampisch HJ, Diehm C (2009) Prevalence of anemia in elderly patients in primary care:impact on 5-year mortality risk and differences between men and women. Curr Med Res Opin 25(5):1143–1158
Estey, E (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25(14):1908–1915
Ewer MS, O’Shaughnessy JA (2007) Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7(8):600–607
Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25(14):1824–1831
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4):1582–1587
Extermann M, Meyer J, McGinnis M et al. (2004) A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49(1):69–75
Facon T, Mary JY, Hulin C et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06):a randomised trial. Lancet 370(9594):1209–1218
Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232
Folstein MF, Folstein SE, McHugh PR (1975) «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460
Frasci G, Lorusso V, Panza N et al. (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18(13):2529–2536
Freyer G, Geay JF, Touzet S et al. (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16(11):1795–1800
Früh M, Rolland E, Pignon JP et al. (2008) Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26(21):3573–3581
Gelman RS, Taylor SGT (1984) Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2(12):1404–1413
Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743
Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24(18):2750–2756
Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB 3rd (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12(11):2447–2452
Goldhirsch A, Gelman RS, Gelber RD, Castiglione M (1990) Treatment of breast cancer in elderly patients. Lancet 336(8714):564
Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ, St Gallen Expert Panel Members (2006) First — select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17(12):1772–1776
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, 10th St. Gallen conference (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–1144
Goldstone AH, Burnett AK, Wheatley K et al. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients:the results of the United Kingdom Medical Research Council AML11 trial. Blood, 2001. 98(5):1302–1311
Goodwin JS, Samet JM, Key CR, Humble C, Kutvirt D, Hunt C (1986) Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 34(1):20–26
Gorner M, Spath-Schwalbe E (2008) Modern treatment options for elderly patients with multiple myeloma. Onkologie 31(6):335–342
Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23(34):8671–8678
Harter P, du Bois A, Schade-Brittinger C et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16(11):1801–1805
Höffken K, Kolb G, Wedding U (2002) Geriatrische Onkologie. Springer, Berlin Heidelberg New York
Honecker F, et al. (2009) Use of the Comprehensive Geriatric Assessment (CGA) in elderly patients (pts) with solid tumors to predict mortality. J Clin Oncol 27(15S):9549 (Abstract)
Hulin C, Facon T, Rodon P et al. (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma:IFM 01/01 trial. J Clin Oncol 27(22):3664–3670
Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067
Albert US (Hrsg) (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Zuckschwerdt, München
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820
Kabbinavar FF, Schulz J, McCleod M (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697–3705
Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27(2):199–205
Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, Bullock R (2004) DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 19(2):136–143
Karnofsky DA, Adelmann WH, Craver FL (1948) The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 1:634–656
Keating NL, Landrum MB, Klabunde CN et al. (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26(15):2532–2537
Kemeny MM, Peterson BL, Kornblith AB et al. (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21(12):2268–2275
Knauf WU, Lissichkov T, Aldaoud A et al. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(26):4378–4384
Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P (2008) Chemotherapy in elderly patients with colorectal cancer. Oncologist 13(4):390–402
Kudoh S, Takeda K, Nakagawa K et al. (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer:results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24(22):3657–3663
Lawton MP, Brody EM (1969) Assessment of older people:self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179–186
Lewis JH, Kilgore ML, Goldman DP et al. 2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389
Lièvre A, Bachet JB, Boige V et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379
Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139
Mahoney FI, Barthel DW (1965) Functional evaluation. Md State Med J 14:61–65
Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr (32):57–71
Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676
Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D (1995) Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) newdrug-development studies. Cancer 76(2):333–338
Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 53(9):2002–2007
Muss HB, Berry DA, Cirrincione CT et al. (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065
Neugut AI, Fleischauer AT, Sundararajan V, Mitra N, Heitjan DF, Jacobson JS, Grann VR (2002) Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 20(11):2643–2650
Nikolaus T, Specht-Leible N, Bach M, Oster P, Schlierf G (1994) Social aspects in diagnosis and therapy of very elderly patients. Initial experiences with a newly developed questionnaire within the scope of geriatric assessment. Z Gerontol 27(4):240–245
Osborne CK, Pippen J, Jones SE et al. (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386–3395
Pallis AG, Gridelli C, Meerbeeck JP van et al. (2009) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol(in print)
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
Pignon JP, Tribodet H, Scagliotti GV et al. (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815
Podsiadlo D, Richardson S (1991) The timed «Up & Go»: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148
Rao AV, Hsieh F, Feussner JR, Cohen HJ (2005) Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci 60(6):798–803
Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, Piccirillo JF (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22(15): 3099–3103
Rehse B, Pukrop R (2003) Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies. Patient Educ Couns 50(2): 179–186
Repetto L, Venturino A, Vercelli M et al. (1998) Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions (see comments). Cancer 82(4): 760–765
Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39(16): 2264–2272
Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16): 1673–1684
Samet J, Hunt WC, Key C, Humble CG, Goodwin JS (1986) Choice of cancer therapy varies with age of patient. Jama 255(24):3385–3390
Sargent DJ, Goldberg RM, Jacobson SD et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097
Sargent DJ, Wieand HS, Haller DG et al. (2005) data from 20,898 patients on 18 randomized trials. J Clin Oncol, 2005. 23(34):8664–8670
Sargent DJ, Patiyil S, Yothers G et al. (2007) End points for colon cancer adjuvant trials:observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25(29):4569–4574
Sargent D, Sobrero A, Grothey A et al. (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27(6):872–877
Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96(17):1311–1321
Schmiegel W, Reinacher-Schick A, Arnold D et al. (2008) (Update S3-guideline «colorectal cancer» 2008). Z Gastroenterol 46(8):799–840
Schmoll HJ, Cartwright T, Tabernero J et al. (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25(1):102–109
Schröder KE, Schwarzer R (1997) Bewältigungsressourcen. In: C. Tesch-Römer, C. Salewski, G. Schwarz (Eds) Psychologie der Bewältigung. Psychologie,: Weinheim, S. 174–195
Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
Sommer G, Fydrich T (1989) Unterstützung:Diagnostik, Konzepte, F-SOZU. Tübingen, Deutsche Gesellschaft für Verhaltenstherapie Statistisches Bundesamt (2010) http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Content/Statistiken/Bevoelkerung/GeburtenSterbefaelle/Tabellen/Content100/SterbetafelDeutschland,property=file.xls. Gesehen 05.01.2010
Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75(1):11–17
Strauß B, Berger U, Troschke J von, Brähler E (2004) Lehrbuch medizinische Psychologie und medizinische Soziologie. Hogrefe, Göttingen
Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342(8878):1032–1036
Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI (2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with nodepositive colon cancer. Ann Intern Med 136(5):349–357
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91(1):66–72
Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34(2):119–126
Tol J, Koopman M, Cats A et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–572
Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA (1994) Representation of older patients in cancer treatment trials. Cancer 74(7 Suppl):2208–2214
Turner NJ, Haward RA, Mulley GP, Selby PJ (1999) Cancer in old age — is it inadequately investigated and treated? BMJ 319(7205):309–312
Twelves C, Wong A, Nowacki MP et al. 2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704
Wagner AD, Wedding U (2009) Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging 26(8):627–646
Watson M, McCarron J, Law M (1992) Anticipatory nausea and emesis, and psychological morbidity: assessment of prevalence among out-patients on mild to moderate chemotherapy regimens. Br J Cancer 66(5):862–866
Watson YI, Arfken CL, Birge SJ (1993) Clock completion: an objective screening test for dementia. J Am Geriatr Soc 41(11):1235–1240
Wedding U, Bokemeyer C, Meran JG (2004) Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). Onkologie 27(1):72–82
Wedding U, Höffken K, Friedrich C, Pientka L (2007a) Health services research and geriatrics: deficits and research approaches using the example of colorectal carcinoma and anaemia. Z Arztl Fortbild Qualitatssich 101(9):587–592
Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K (2007b) Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14(1):44–56
Wedding U, Honecker F, Pienkta L, Höffken K (2007c) Klinische Studien und Patientregister für alte Patienten mit Krebserkrankungen. Onkologe 13(9):783–791
Wedding U, Röhrig B, Pientka L, Höffken K (2007d) Anaemiarelated impairment in quality of life in elderly cancer patients prior to chemotherapy. J Cancer Res Clin Oncol 133(5):279–286
Wedding, U., et al. (2008) Comprehensive Geriatric Assessment (CGA) in elderly patients with hematological neoplasia: CGA and not age predicts mortality — Results from in-GHO-Registry. Blood 112(11):1310 (Abstract)
Wehling M (2008) Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA). Dtsch Med Wochenschr 133(44):2289–2291
Wehling M (2009) Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 57(3):560–561
Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA (2008) Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(14):2350–2357
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17(1):37–49
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wehling, M., Burkhardt, H., Schwarz, S., Frölich, L., Wedding, U. (2010). Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch klinischer Bedeutung. In: Arzneitherapie für Ältere. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10215-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-10215-8_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-10214-1
Online ISBN: 978-3-642-10215-8
eBook Packages: Medicine (German Language)